Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
NATIONAL INSTITUTES OF HEALTH has floated a tender for Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (Ug3/Uh3 Clinical Trial Optional). The project location is USA and the tender is closing on 11 Nov 2021. The tender notice number is RFA-DA-22-022, while the TOT Ref Number is 56220834. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (Ug3/Uh3 Clinical Trial Optional)
Deadline : 11 Nov 2021
Other Information
Notice Type : Tender
TOT Ref.No.: 56220834
Document Ref. No. : RFA-DA-22-022
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : NATIONAL INSTITUTES OF HEALTH
NIH OER WebmasterOERWebmaster03@od.nih.gov
USA
Email :OERWebmaster03@od.nih.gov
Tender Details
Tender are invited for Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)
CFDA Number : 93.279 -- Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Nov 11, 2021
Posted Date : Aug 12, 2021
Description: The purpose of this Funding Opportunity Announcement is to support research to understand and respond to new challenges in the treatment of drug addiction and overdose, introduced by the now widespread presence of fentanyl and its analogs (fentanils) in illicit drug supplies. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Applications may focus on the treatment of opioid and polydrug use disorders where fentanils are a major contributor to the problem. The research may include preclinical, clinical, epidemiological or post-mortem studies, but should have high impact and quickly yield the necessary information to understand and ef...
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google